FDA Inspection 1310504 — Omnivium Pharmaceuticals LLC
The FDA completed an inspection of Omnivium Pharmaceuticals LLC on Mar 27, 2026 in Rahway, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Mar 27, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Rahway, NJ (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)